Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pixantrone + Rituximab + Fludarabine in Indolent NHL
NCT00551239Phase 3Withdrawn
- Sponsor
- CTI BioPharma Corp.
- Start
- Aug 2007
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pixantrone in Indolent Non-Hodgkin Lymphoma (INHL) (2 arms), sponsored by CTI BioPharma Corp. Primary endpoint: Progression-Free Survival. Planned start Aug 2007; status: withdrawn.
02
Drugs
pixantrone
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT00551239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00551239.